DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Buzdar AU, Ibrahim NK, Francis D. et al.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer.
J Clin Oncol 2005;
23 (16) 3676-3685
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.